Skip to content
DataLookout
Menu

NCT05755620

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

StatusCompleted
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 73 versions: 4 with changes below, 46 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 19, 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 56 words
    • Primary endpoints: 9 to 8
    • Secondary endpoints revised (6)
    • Study arms: 5 to 4
  2. Minor Trial status: Active, Not Recruiting to Completed
    • Primary and study completion dates changed from estimate of Dec 4, 2025 to Oct 3, 2025
    v71
  3. Minor Primary and study completion dates: Aug 20, 2025 to Dec 4, 2025v65
  4. Notable Enrollment target: 30 to 50v62
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number and Percentage of Participants Experiencing Solicited Local and Systemic Reactogenicity Adverse Events (AEs)
Timeframe: Day of vaccination through 13 days post-vaccination
Number and Percentage of Participants Experiencing Any Unsolicited AEs
Timeframe: Day of vaccination through 28 days post-vaccination
Number and Percentage of Participants Experiencing Any New-onset Chronic Medical Conditions (NOCMCs)
Timeframe: Day of vaccination through end of study participation (approximately 365 days post-vaccination)
Number and Percentage of Participants Experiencing Any Adverse Events of Special Interest (AESIs) Corresponding to Grade 2 or Greater Decrease in Lymphocyte or Neutrophil Count
Timeframe: Day of vaccination through end of study participation (approximately 365 days post-vaccination)
Number and Percentage of Participants Experiencing Any Influenza-like Illnesses (ILIs)
Timeframe: Day of vaccination through end of study participation (approximately 365 days post-vaccination)
Number and Percentage of Participants Experiencing Any Serious Adverse Events (SAEs)
Timeframe: Day of vaccination through end of study participation (approximately 365 days post-vaccination)
Number and Percentage of Participants Experiencing AESIs Corresponding to Myocarditis, Pericarditis, or Myopericarditis
Timeframe: Day of vaccination through 56 days post-vaccination
Number and Percentage of Participants Experiencing Clinical Laboratory AEs
Timeframe: Day of vaccination through 56 days post-vaccination

Secondary (6)

Geometric Mean Titers (GMT) of Homologous H1-specific Neutralizing Antibodies in a Reporter Microneutralization Assay
Geometric Mean Fold Rise (GMFR) of Homologous H1-specific Neutralizing Antibodies in a Reporter Microneutralization Assay
Geometric Mean Titers (GMT) of Homologous H1-specific Neutralizing Antibodies in a Viral Microneutralization Assay
Geometric Mean Fold Rise (GMFR) of Homologous H1-specific Neutralizing Antibodies in a Viral Microneutralization Assay
Geometric Mean Titers (GMT) of Anti-stalk Serum Antibodies, Measured by Enzyme Linked Immunosorbent Assay (ELISA)
Show 1 moreShow less
Geometric Mean Fold Rise (GMFR) of Anti-stalk Serum Antibodies, Measured by Enzyme Linked Immunosorbent Assay (ELISA)

Arms and interventions

Arm 1, Low DoseExperimental

10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 10 mcg of the H1ssF\_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 10 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. N = 10

Arm 2, Medium DoseExperimental

10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 25 mcg of the H1ssF\_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 25 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. N = 10

Arm 3, High DoseExperimental

Experimental: Arm 3, High Dose 10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 50 mcg of the H1ssF\_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 50 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. The High Dose was selected as the optimal dose as it was the highest dose with no identified safety concerns by the Safety Review Committee (SRC). An additional 10 (optimal dose) participants were therefore enrolled into the High Dose group. Total N = 20

Arm 4, IIV4Active comparator

10 healthy adult volunteer subjects from 18-49 years of age will receive licensed Quadrivalent Influenza Vaccine (IIV4), administered intramuscularly once. Subjects receiving IIV4 will be followed for safety, but only their immune responses will be compared to those of participants receiving H1ssF\_3928 mRNA Vaccine. N=10

Biologicals: Influenza Virus Quadrivalent Inactivated Vaccine, VRC-FLUNPF099-00-VP (H1ssF_3928)

Other: Sodium Chloride, 0.9%

Sites

1 site in 1 country

  • Duke Vaccine and Trials UnitDurham, North Carolina, United States